- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Natco Pharma unveils first generic version of Pomalyst capsules in Australia
Pomalidomide is prescribed for treatment of Multiple Myeloma and Kaposi Sarcoma.
Hyderabad: Drugmaker, NATCO Pharma Limited, today announced the launch of first generic version of Pomalyst (Pomalidomide) Capsules in 1,2,3,4 mg strengths in the Australian market.
The product was launched by NATCO's commercial partner Juno Pharmaceuticals Pty Ltd.
Pomalidomide is prescribed for the treatment of Multiple Myeloma and Kaposi Sarcoma.
Multiple myeloma is an uncommon type of blood cancer in which abnormal plasma cells build up in the bone marrow and form tumors in many bones of the body. This disease keeps the bone marrow from making enough healthy blood cells, which can result in low blood counts. Myeloma can also damage the bones and the kidneys and weaken the immune system.
Read also: NATCO Announces Launch of the First Generic Version of Revlimid, in the U.S. market
Pomalyst registered sales of USD 35.6 million in the Australian market for the year ending 31st March 2022 as per industry sales data.
Pomalyst is a registered trademark of Celgene/BMS. All brand names and trademarks are the property of their respective owners.
Read also: Natco Pharma launches Chlorantraniliprole (CTPR) pesticide formulated combination products in India
Natco Pharma Limited is a vertically integrated and R&D-focused pharmaceutical company engaged in developing, manufacturing, and marketing of finished dosage formulations ("FDF") and active pharmaceutical ingredients ("APIs"). The company focuses primarily on niche therapeutic areas and complex products. Natco market and distribute its products in over 40 countries.
Natco sells its FDF products in the United States, India, Europe, and the rest of the world ("RoW"). In the API segment, the company has the capabilities to develop and manufacture products with multi-step synthesis, semi-synthetic fusion technologies, high-potency APIs, and peptides.
The company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.
Read also: Natco Pharma partner Viatris to launch first generic version of Nexavar tablets in US
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751